EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis
NCT: NCT07620080 · NOT_YET_RECRUITING
Brief Summary
Cholangiocarcinoma remains difficult to diagnose because of the limited sensitivity of currently available endobiliary sampling techniques. Cholangioscopy-guided biopsies performed with the SPYGLASS™ DS system have improved tissue acquisition compared with conventional brushing techniques, but diagnostic sensitivity remains suboptimal, partly because of the small diameter of the dedicated biopsy forceps. The EYEMAX® cholangioscopy system has a larger working channel, potentially allowing the use of larger biopsy forceps and improved tissue acquisition. This multicenter randomized study aims to compare the diagnostic performance of EYEMAX® versus SPYGLASS™ DS for the diagnosis of malignant biliary strictures. The primary objective is to compare the positive diagnostic yield of the first four cholangioscopy-guided biopsies obtained with each system in patients with adenocarcinomatous biliary strictures.
Frequently Asked Questions
What is EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis?
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis is a clinical trial registered under NCT07620080. Current status: NOT_YET_RECRUITING.
What is the status of NCT07620080?
The current status of NCT07620080 (EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis) is: NOT_YET_RECRUITING.
When did EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis start?
EYEMAX® Versus SPYGLASS™ DS for Biliary Stricture Diagnosis started on 2026-09.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.